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Background: Patients with cystic fibrosis and normoglycemia (CF-NGT) have higher but still “normal” glucose levels in the Oral Glucose Tolerance
Test (OGTT). Respiratory exacerbation is associated with metabolic stress. The objective of this study was to assess the glucose metabolism and its
relation to the steady state pulmonary function (FEV1) in patients with CF-NGT, specifically during pulmonary exacerbations (PE).
Methods: CF-NGT patients who were not on steroids, underwent OGTT and intravenous glucose tolerance tests (IVGTT) during PE and 4 weeks
after complete recovery.
Results: Of the ten recruited patients two had diabetic OGTT and were excluded. The remaining normoglycemic patients displayed during PE a
diabetic glucose tolerance with mean glucose levels of 233±8 and 262±11 mg/dl at 90 and 120 min respectively, compared with normal levels of
154±21and 126±20 mg/dl (pb0.002) during the steady state. IVGTT showed a tendency to higher first phase insulin release during PE compared
with the steady state.(min 3; 305±80 vs. 216±40 pmol\l p=0.075). Finally, when relating the diabetic status to the general respiratory function we
found a negative correlation between baseline FEV1 and glucose levels at 2 h after OGTT during PE (r=−0.88, p=0.002).
Conclusion: In this pilot study we show that during PE patients with CF and normal glucose tolerance exhibited early latent diabetic glucose
intolerance. As this hyperglycemia presents in the later parts of the OGTT it probably results from insufficient second phase insulin secretion
during PE. The negative correlation observed here between the diabetic glucose tolerance and FEV1 indicate the need of interventional studies
using insulin during PE in non-diabetic patients to determine its potential benefit on the outcome from recurrent PEs.
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doi:10.1016/j.jcf.2010.02.001a recent general survey, 19.5% of patients with cystic fibrosis (CF)
hadCFRDor impaired glucose tolerance and at the age of 30 years
nearly 30% of patients with CF had CFRD [1–3]. Decreased
pulmonary function, a decline in nutritional status, growth
retardation in pubertal patients, and deterioration of the patient's
general healthwere all shown to be associatedwith the presence of
CFRD [4–6]. Moreover, the mortality rate among patients with
CF and CFRD is six times higher compared with those without
diabetes [7]. The early diabetic or impaired glucose tolerance
(IGT) period may also accelerate the decline in the clinical status
of patients with CF, years prior to the development of overt CFRD
[4,8,9]. Therefore it has been recommended to perform an annual
Oral Glucose Tolerance Test (OGTT) in patients over the age of
10 years, in order to detect early alterations in glucose homeostasisd by Elsevier B.V. All rights reserved.
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accordingly [10–12].
The pathophysiology of CFRD is not fully understood,
however, impaired beta-cell secretion due to pancreatic fibrosis
and the progressive destruction of the pancreatic islet
architecture is thought to be the main mechanism [12–14].
The role of insulin resistance in the pathogenesis of CFRD
remains unclear given several conflicting studies [15–21]. In
addition there is evidence for a specific role for the cystic
fibrosis transmembrane conductance regulator (CFTR) protein
deficiency in islet and beta-cell dysfunction [22,23].
Interestingly, even in patients with CF and normal glucose
tolerance (CF-NGT) the glucose metabolism seems aberrant as
the area under the glucose curve in OGTT is significantly higher
and its peak plasma insulin concentration is decreased and
delayed compared to healthy controls [24]. In patients with CF
acute pulmonary exacerbations (PE), caused by infection and
inflammation, are stressful conditions. As stress may unmask
early alterations in glucose homeostasis [25,26] we have
analyzed the metabolism of glucose in patients with CF who
are non-diabetic with normal glucose tolerance (CF-NGT)
specifically during acute PE.
2. Patients and methods
2.1. Patients
Patients with CF over 10 years of age with pancreatic
insufficiency and NGT (according to the last routine OGTT
performed within 3–12 months prior to the study) with no steroid
therapywere included in the study.Acute PEwas defined by three
or more of several criteria including: an increase in cough and/or
in sputum production and/or shortness of breath associated with
fatigue, new findings upon chest auscultation, over10% reduction
in pulmonary function and loss of appetite and weight that
according to the treating physician (EK, DS) required treatment
with intravenous antibiotics [27]. All the patients underwent a
complete physical examination, nutritional assessment and
spirometry testing before the initiation of intravenous antibiotic
therapy. Intravenous glucose tolerance test (IVGTT) was done in
all patients within 48 h after the initiation of the intravenous
antibiotic therapy followed by OGTT on the next day. Our main
outcome was to assess whether our patients fulfill the standard
criteria of the definition of diabetes during exacerbation and
whether they have a normal first phase insulin secretion capacity
during IVGTT. These tests were repeated 4 weeks after complete
resolution of the PE (usually 6 weeks following the initiation of
the exacerbation). Thus, each patient served as his own control.
2.2. IVGTT
The test was performed using 0.5 g/kg (maximum 35 g) of
25% glucose solution, administered through a peripheral vein
during 3±0.25 min [28]. Venous blood was sampled at −5, 0, 1,
3, 5, and 10 min after glucose infusion. Plasma glucose levels
were recorded using a YSI 2700 glucose analyzer (Yellow
Springs Instruments, Yellow Springs, OH). Insulin levels weremeasured by radioimmunoassay (Linco Research, St. Charles,
MO).
The area under the curve (AUC) for glucose and insulin was
calculated using the trapezoidal estimation. First phase insulin
secretion capacity was calculated as AUC of 1+3 min of insulin
in IVGTT during steady state.
2.3. OGTT
A standard OGTT was performed, namely, a 50% glucose
solution at a dose of 1.75 g/kg body weight (maximum 75 g)
was administered orally. As recurrent venous access and
compliance were expected to be limited especially during
steady state (as it did follow by at least 24 h the IVGTT) we
chose to use the glucometer for glucose measurements in spite
of its limitations (e.g. an average of 10–20% higher readings
than in the laboratory). Blood glucose was sampled by an Accu-
Chek glucometer (Roche Diagnostics Ltd) at baseline and at 30,
60, 90 and 120 min. The AUC was calculated using the
trapezoidal estimation. The study was approved by the
Institutional Review Board of the Hadassah-Hebrew University
Medical Center and written informed consent was obtained
from all the study participants and/or parents.
2.4. Statistical analysis
Results are presented as mean±SE. The non-parametrical
Wilcoxon sign rank test was used for analysis and comparison
of glucose and insulin levels, and for comparison of their AUC
in various time points. The Spearman correlation of a number of
variables was used to study the relation between the variables.
Results were considered significant at pb0.05. All analyses
were conducted using SAS 9.1.3 (SAS Institute Inc, Cary, NC).
3. Results
Ten patients (6 males/4 females) with CF were enrolled in
the study with a mean age of 19±1.2 years [13y–23y]. All ten
patients had class I and II mutations. Eight were compound
heterozygotes for CF known mutations and 2 were homozy-
gous. 7 compound heterozygotes had the combination of
W1282X/DELTA F508 mutations. Pulmonary exacerbation
was diagnosed based on various clinical symptoms and signs as
described in the methods. Mean FEV1% was lower but not
significantly different when comparing 57.2±5.7% during PE
and 62.4±6.5% 6 weeks later during steady state. Mean weight
(kg) was 49.68±3.1 (BMI-19.1) and ±3.2 (BMI-19.8) during
PE and after treatment respectively. None of the patients
received steroid therapy during the exacerbation.
3.1. OGTT
The results of OGTT during PE, i.e., Oral Glucose Tolerance
Stress Test (OGTST) and in the steady state are shown in Fig. 1.
Two of the 10 patients had diabetic OGTT in the steady state, and
therefore were excluded from the study and initiated on insulin
therapy. The remaining patients (excluding one who had
Fig. 1. Blood glucose levels in Oral Glucose Tolerance Test – OGTT during
pulmonary exacerbation – (triangle) compared to OGTT during the steady state
(square). *90 and 120 min p=0.0078.
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glucose tolerance at the onset of PE with mean (±SE) glucose
levels of 233±8 mg/dl (range 180–357) and 262±11 mg/dl
(range 181–346) at 90 and 120 min respectively. After recov-
ery from PE blood glucose levels returned to the normal range of
154±21 mg/dl, (range 119−192), 126±20 mg/dl, (range 100−
141) respectively (p=0.008). No difference was detected between
exacerbation and steady state studies in mean glucose levels at
0 and 30 min time points of OGTT. Additionally, mean AUC in
OGTT during PE was higher then mean AUC during steady state
(19,539±1932 vs. 14,780±1134, p=0.008).
3.2. IVGTT
Two patients did not consent to perform IVGTT due to
known difficulties in their intravenous access on prior admis-
sions. When comparing the IVGTT results during PE andFig. 2. A. Insulin levels during IVGTT in pulmonary exacerbations (triangle) com
between glucose levels during pulmonary exacerbations (using AUC of OGTT) and t
insulin secretion of IVGTT) in the steady state. R=−0.64, p=0.09.following steady state we found no differences in either glucose
or insulin levels. After IV glucose challenge insulin levels were
not lower during PE; in fact there was a tendency (though not
significant) towards higher insulin release during PE when
compared with steady state. At 3 min after glucose load insulin
secretion was higher (305±80 pmol/l vs. 216±40 pmol/l,
p=0.075, Fig. 2A) and overall the ratio between the AUC of
insulin and the AUC of glucose during IVGTT was higher
during PE as compared with the values at steady state; (1.06±0.2
vs. 0.75±0.1 respectively (p=0.06)).
In order to analyze whether reduced insulin secretion capacity
contributes to the high glucose levels during PE we examined the
correlation between glucose levels during PE (using AUC of
OGTT) and the basal insulin secretion capacity during steady state
(using the early first phase [AUC of 1+3 min] insulin secretion of
IVGTT). A tendency toward negative correlation was detected
(r=−0.64, p=0.09) although it did not reach statistical
significance (Fig. 2B).
3.3. Correlation between FEV1 and glucose levels during
exacerbation
As CFRD has been previously associated with worsening of
the general clinical status in patients with CF we analyzed the
correlation between basal FEV1 (stable values that were
measured during routine visits every month prior to the
exacerbation) and the glucose levels during PE. A negative
correlation was found between the steady state FEV1 and glucose
levels during PE 2 h post OGTT (r=−0.88, p=0.002); this
implied that steady state FEV1 was significantly better in those
patients who displayed lower glucose levels during PE (Fig. 3).
4. Discussion
Patients with CF are routinely surveyed for the development
of diabetes by an annual OGTT screening that detects IGT orpared to the steady state (square). *3 min time point p=0.075. B. Correlation
he basal insulin secretion capacity (using the early first phase [AUC of 1+3 min]
Fig. 3. Correlation between FEV1 in the steady state and the 2 h glucose levels
in OGTT during pulmonary exacerbation. R=−0.88, p=0.002.
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carry class I and II mutations of CFTR like all of our study
groups may be at higher risk for the development of CFRD [30]
and probably should be more carefully monitored. To the best of
our knowledge, glucose metabolism during PE in patients with
CF but without diabetes has not yet been studied. The results of
this pilot study show that patients with CF and normal glucose
tolerance display a diabetic or very near glucose tolerance during
PE. The studied patients who did not have glucose intolerance in
the past OGTTs, exhibited hyperglycemia averaging over
230 mg/dl at 120 min of OGTT during PE which completely
normalized 6 weeks later after resolution of the PE.
In order to analyze the mechanism responsible for this
hyperglycemia in non-diabetic patients we evaluated the first
phase of insulin secretion in IVGTT. Few studies that
evaluated IVGTT in patients with CF, though not during PE,
found lower levels of first phase insulin secretion compared
with healthy subjects [31,32]. Tofé et al. have recently
demonstrated a significant decrease in peak, first phase and
total insulin secretion in patients with CF and impaired glucose
tolerance (CF-IGT) compared to patients with CF and normal
glucose tolerance (CF-NGT) [33]. In our patients with CF-
NGT, the first phase insulin secretion during exacerbation was
not decreased but possibly slightly increased; although no
difference was observed in the IVGTT glucose levels. This
finding indicated a residual beta-cell secretion capacity to meet
immediate needs in conditions that are characterized by higher
insulin resistance such as infection or other causes of stress
[34,35]. But, although the insulin output from the beta-cells of
CF-NGT patients were not decreased at the early hyperglyce-
mic stages in both OGTT and IVGTT, it was not enough to
prevent the later stage hyperglycemia observed at 90 and
120 min in the OGTT performed during exacerbation. Since
insulin resistance is relatively constant along the 2 h length of
OGTT, it is likely that while insulin secretion capacity in the
first phase during PE was comparable to the pulmonary steady
state it failed to persist for the ongoing needs at 60–120 min
following the glucose load in PE. Chronic impairment of
glucose tolerance and insulin secretion has been shown to
correlate with the rate of decline in lung function in patientswith CF [9]. Some studies demonstrated improvement in
pulmonary function and nutrition status after insulin admin-
istration in patients with CF [36–39], possibly due to the
anabolic effect of insulin [36,40,41]. Our observation that
patients with CF with normal OGTT may have diabetic OGTT
during PE may have clinical significance. These patients who
are considered to be normloglycemic may experience relative-
ly long periods of hyperglycemia during their recurrent events
of infections. The exposure to hyperglycemia may adversely
affect their general pulmonary and nutritional status as has
been shown for CFRD.
Furthermore, in this study a negative correlation was
observed between baseline FEV1 in the steady state and
glucose levels at the 120 min time point in the OGTT during PE
of CF-NGT patients. It could be that patients with a more severe
lung disease are at the early stage of CFRD that can be detected
only during stress. Alternatively the negative correlation may
indicate that chronically increased glucose values during PE
have an adverse impact on pulmonary function. In either way it
would be important to follow these patients over a long time to
see if the patients with higher glucose levels during PE are
prone to develop CFRD earlier. Traditionally, OGTT during
steady state has been used as the reference point for the
introduction of insulin therapy. However, based on this pilot
study, adding insulin during PE associated with hyperglycemia
needs to be considered and may improve immediate and future
outcomes. In the short term, administration of insulin may
improve the glycemic state, prevent the favorable effect of
hyperglycemia on the growth of respiratory pathogens [42]
avoid the deleterious effect of hyperglycemia per-se during
stressful conditions as in the ICU [25,26,43–46] and possibly
enhance the recovery. In the long term, it may have a potential
of both improving the general clinical condition of these
patients and also have a protecting effect on the beta-cells by
preventing the deleterious effect of chronic hyperglycemia
[47,48]. The finding of only a trend rather than a significant
negative correlation between glucose levels during PE and first
phase insulin secretion during steady state is probably due to the
relative small number of patients in our study. Recruiting
patients and performing both OGTT and IVGTT in both PE and
6 weeks later in the steady state was not trivial especially given
the relatively young age of the patients in our clinic and the low
rates of severe exacerbations. Although this correlation did not
reach statistical significance it may suggest that the patients
with lower insulin secretion in steady state can maintain normal
sugar during steady state however during PE not enough insulin
is produced to normalize glucose levels. Further studies are
needed to establish whether lower first phase insulin secretion in
the steady state of CF-NGT patients can serve as a predictor for
their glucose function during exacerbation.
In conclusion, our pilot study shows for the first time that
during pulmonary exacerbations, patients with CF and normal
glucose tolerance exhibit a diabetic glucose tolerance test.
This altered glucose metabolism probably results from a
limited second phase insulin secretory capacity and is
associated with a more severe lung disease at baseline.
Further and larger studies are needed to determine whether
203N.N.M. Sc et al. / Journal of Cystic Fibrosis 9 (2010) 199–204insulin therapy during PE in these CF-NGT patients may have
a beneficial effect on the recovery from exacerbation, the rate
of decline of pulmonary function and the future development
of CFRD.
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